Anebulo Pharmaceuticals - ANEB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.67
  • Forecasted Upside: 207.22%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.17
▼ -0.05 (-2.25%)

This chart shows the closing price for ANEB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Anebulo Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANEB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANEB

Analyst Price Target is $6.67
▲ +207.22% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Anebulo Pharmaceuticals in the last 3 months. The average price target is $6.67, with a high forecast of $8.00 and a low forecast of $6.00. The average price target represents a 207.22% upside from the last price of $2.17.

This chart shows the closing price for ANEB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Anebulo Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/3/2023BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$8.00Low
9/25/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
9/21/2023Maxim GroupInitiated CoverageBuy$6.00Low
9/18/2023HC WainwrightInitiated CoverageBuy$6.00Low
2/14/2023BenchmarkLower TargetSpeculative Buy$10.00 ➝ $8.00Low
7/27/2022LADENBURG THALM/SH SHInitiated CoverageBuy$6.00Low
5/17/2022BenchmarkLower TargetNA$15.00 ➝ $10.00Low
5/25/2021BenchmarkInitiated CoverageBuy$15.00Low
(Data available from 5/24/2019 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/27/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/26/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/24/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/24/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/24/2024

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Anebulo Pharmaceuticals logo
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
Read More

Today's Range

Now: $2.17
Low: $2.05
High: $2.23

50 Day Range

MA: $2.69
Low: $2.10
High: $3.12

52 Week Range

Now: $2.17
Low: $1.62
High: $4.05

Volume

4,161 shs

Average Volume

5,686 shs

Market Capitalization

$56.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Anebulo Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Anebulo Pharmaceuticals in the last year: Benchmark Co., HC Wainwright, and Maxim Group.
View the latest analyst ratings for ANEB.

What is the current price target for Anebulo Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Anebulo Pharmaceuticals in the last year. Their average twelve-month price target is $6.67, suggesting a possible upside of 207.2%. Benchmark Co. has the highest price target set, predicting ANEB will reach $8.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $6.00 for Anebulo Pharmaceuticals in the next year.
View the latest price targets for ANEB.

What is the current consensus analyst rating for Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ANEB will outperform the market and that investors should add to their positions of Anebulo Pharmaceuticals.
View the latest ratings for ANEB.

What other companies compete with Anebulo Pharmaceuticals?

How do I contact Anebulo Pharmaceuticals' investor relations team?

The company's listed phone number is 512-598-0931 and its investor relations email address is [email protected]. The official website for Anebulo Pharmaceuticals is www.anebulo.com. Learn More about contacing Anebulo Pharmaceuticals investor relations.